Overview SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I Status: Withdrawn Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary A multi-institutional, prospective, randomised, open-label, superiority, comparative, active-controlled, phase 3 study. The study will compare Synergo RF-induced hyperthermia-chemotherapy (SHTC) plus mitomycin C (MMC) to standard treatment of bacillus Calmette-Guérin (BCG) therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC, and will evaluate recurrence and progression rate over two years of follow-up. Phase: Phase 3 Details Lead Sponsor: Medical Enterprises Europe B.V.Treatments: BCG VaccineMitomycinMitomycins